Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis A Prospective, Multi-centre, Non-randomized Clinical Trial With Follow-up Investigations at 1, 6 and 12 Months

Biotronik AG1 site in 1 country81 target enrollmentAugust 2009

ConditionsIn-stent Coronary Artery Restenosis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: In-stent Coronary Artery Restenosis
Sponsor: Biotronik AG
Enrollment: 81
Locations: 1
Primary Endpoint: In-stent Late Lumen Loss
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study is to evaluate the safety and efficacy of the paclitaxel releasing balloon in patients with in-stent restenosis in a coronary artery.

Detailed Description

All patients are treated with the paclitaxel releasing balloon Pantera Lux. The indication is in-stent restenosis in either bare metal stent (BMS) or drug eluting stent (DES). Clinical follow up visits at 1, 6 and 12 months. Angiographic follow up visit at 6 months.

Registry

clinicaltrials.gov

Start Date

August 2009

End Date

May 2011

Last Updated

12 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Biotronik AG

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient \>/= 18 years
•Written patient informed consent available
•Patients with stable, unstable or documented silent angina pectoris
•Patient eligible for percutaneous coronary intervention
•Patient acceptable candidate for coronary artery bypass surgery
•Patients with a single restenotic lesion in a previously stented area of a coronary artery (irrelevant whether BMS or DES related)
•Target reference vessel diameter (visual estimation): 2 - 4 mm
•Target lesion length (visual estimation): 8 - 28 mm
•Target lesion stenosis (visual estimation): \>/= 50% - \< 100%

Exclusion Criteria

•Left ventricular ejection fraction of \< 30%
•Visible thrombus in the target vessel visualized by angiography
•Myocardial infarction (STEMI/NSTEMI) within 72 hours of the intended treatment. Determination of CKMB and/or troponin T or I is required.
•Laboratory assessments to be done within 24 hours prior to intervention. Patients with CKMB and/or troponin T or I \> 2 fold the upper limit of normal must not be included in the trial.
•Patients with planned major surgery within 3 months after planned coronary intervention and/or risk of either acetylsalicylic acid of clopidogrel cessation
•Lesion length longer than length of available treatment balloon
•Impaired renal function (serum creatinine \> 2.0mg/dl or 177 micro mol/l, determined within 72 hours prior to intervention)
•Additional coronary lesions (restenotic or de novo) in the same vessel which requires treatment
•Totally occluded coronary artery (Mehran classification IV and TIMI flow 0)
•Target lesion located in vessel bifurcation

Outcomes

Primary Outcomes

In-stent Late Lumen Loss

Time Frame: 6 months

In-stent is defined as from proximal shoulder to distal shoulder of the dilated Pantera Lux balloon. Late lumen loss is defined as the difference between minimal luminal diameter after procedure and at 6 months, as evaluated by offline quantitative coronary angiography (QCA). Offline quantitative coronary angiography (QCA) analysis was performed by an independent core laboratory (Ulrich Dietz, MD, Deutsche Klinik für Diagnostik, Wiesbaden, Germany).

Secondary Outcomes

In-segment Late Lumen Loss(6 months)
Cumulative Major Adverse Cardiac Events Rate (Composite of Cardiac Death, Non-fatal Myocardial Infarction, Clinically Driven Target Lesion Revascularization, Clinically Driven Target Vessel Revascularization)(6 months)
Cumulative MACE Rate (Composite of Cardiac Death, Non-fatal MI, Clinically Driven TLR, Clinically Driven TVR)(12 months)
In-stent Diameter Stenosis (%DS)(6 months)
In-segment Diameter Stenosis (%DS)(6 months)
Binary In-stent Restenosis(6 months)
Binary In-segment Restenosis(6 months)
Technical Success(directly after intervention (after finalized treatment))
Device Success(directly after intervention (after finalized treatment))